Eyecarrot Awarded Funding From the Government of Canada to Commercialize Its Innovative Binovi Saccadic Fixator
Toronto, Ontario – Eyecarrot Innovations Corp TSX-V: EYC is pleased to announce that it has been awarded up to $149,990 in funding by the National Research Council of Canada-Industrial Research Assistance Program (NRC-IRAP) for the commercialization of the company’s Binovi Saccadic Fixator, which will integrate seamlessly with its BinoviTM platform (currently in private beta). The Saccadic Fixator was originally created in 1974 by industry pioneer and innovator Harry Wayne, and was the first tool to use the combination of electronics and hardware to train and enhance the Oculomotor Sensory System (OMS). With the acquisition of Wayne Engineering in 2015, Eyecarrot has access to over three thousand (3,000) existing Saccadic Fixator customers globally. The company is excited to bring modern technology advancements to these customers via the BinoviTM platform, enabling a world-class patient experience by seamlessly integrating software, hardware, data, and expert knowledge of vision care professionals. Eyecarrot’s Binovi Saccadic Fixator is the first of several planned hardware devices that will integrate with its BinoviTM cloud-based platform.
“Recent research has confirmed that training of the OMS (Oculomotor Sensory system) plays a vital role in the treatment of various vision-related learning issues, recovery from concussions and other traumatic brain injuries, and the enhancement of vision performance in amateur and professional sports. Advancing our BinoviTM platform to include hardware instrumentation, the seamless capture of data and reporting of insightful analytics will contribute to our goal of transforming how OMS performance is diagnosed, exercised and enhanced globally. We are grateful to NRC-IRAP for their support in helping us commercialize this innovative leap forward for the industry-standard Saccadic Fixator.”
Adam Cegielski, CEO
The Company has also granted an aggregate of 6,660,000 options to Directors, Officers, Employees, and Consultants, having a three (3) year term and exercisable at a price of $0.25 per share.
